10 Analysts Have This to Say About Five9

Analysts have provided the following ratings for Five9 (NASDAQ:FIVN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

Analysts have provided the following ratings for Five9 (NASDAQ:FIVN) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 7 1 2 0 0
Last 30D 0 0 1 0 0
1M Ago 2 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 4 1 1 0 0

According to 10 analyst offering 12-month price targets in the last 3 months, Five9 has an average price target of $91.5 with a high of $105.00 and a low of $75.00.

Below is a summary of how these 10 analysts rated Five9 over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has increased by 13.2% from the previous average price target of $80.83.

Stay up to date on Five9 analyst ratings.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Watching Bausch Health Companies; Seeking Alpha Reports, Court Ruling In Patent Dispute With Norwich Pharma; Court Issued An Order Denying Norwich’s Motion To Modify Judgment In The Case Of: “Salix Pharmaceuticals, Ltd. Norwich Pharmaceuticals, Inc.”

https://seekingalpha.com/news/3972676-bausch-health-soars-after-court-ruling-in-patent-dispute-with-norwich-pharma?utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated Bausch Health (NYSE:BHC) soared 40% after a court ruling related to the company’s patent suit vs Norwich Pharma over…

BHC

Read More

Analyst Ratings for Wynn Resorts

  Over the past 3 months, 4 analysts have published their opinion on Wynn Resorts (NASDAQ:WYNN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

WYNN